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ABSTRACT

Objective: The objective of this selective EBM review is to determine whether or not “Does
onabotulinumtoxin type A reduce interference of daily activities for adults with hyperhidrosis?”
Study Design: A systematic review of three randomized control trials (RCTs) published after
2009 in peer-reviewed journals in the English language. These RCTs compared the efficacy of
onabotulinumtoxin type A (BTX-A) to other treatment modalities in reducing the interference of
daily activities for adults with hyperhidrosis.
Data Sources: Three RCTs were selected after searching the databases Pubmed, CINAHL plus,
International Pharmaceutical Abstracts, and Central Register of Controlled Trials. Inclusion
criteria was relevant studies published after 2009. Exclusion criteria was patients under 18 years
old, too few subjects used in trial, and if the article was a systematic review or meta-analysis.
Outcomes Measured: The outcome measured was a reduction in interference of daily activities
from hyperhidrosis. This was assessed via the hyperhidrosis disease severity scale (HDSS), a
four-point subjective scale with a score of one correlating to no daily activity interference from
sweating and a score of four correlating to constant interference.
Results: In the RCT conducted by Ibrahim et al., the mean HDSS scores were reduced by 1.55
points 3 months after the administration of onabotulinumtoxin type A (P<.001). In the RCT
conducted by Campanati et al., every patient had a 2-point reduction in HDSS scores from
baseline compared to 4 weeks after intervention with BTX-A, a statistically significant reduction
(P<.001). The RCT conducted by Lueangarun et al., resulted in a reduction of 1.35 points on the
HDSS scale four weeks after BTX-A cream application compared to baseline; when compared to
the reduction of the control group this was statistically significant (P<.001).
Conclusion: All three RCTs found a reduction in daily activity interference due to hyperhidrosis
with the implementation of onabotulinumtoxin type A. Although there were limitations to the
studies, these findings suggest that onabotulinumtoxin type A is effective in reducing activity
interference for those with primary hyperhidrosis.
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INTRODUCTION
Hyperhidrosis is a condition characterized by excessive perspiration extending beyond its
physiologic purpose in maintaining body temperature during exercise or heat exposure. This
excessive sweating typically affects the palms of the hands, soles of the feet, axilla, and face.1,2,3
Secondary hyperhidrosis has an identifiable cause, and is related to an underlying medical
condition such as infection, hormonal imbalance, or medication side effect.2 In contrast, primary
hyperhidrosis is idiopathic and chronic in nature, often with a symmetric and bilateral
distribution of affected areas.1 While the cause of primary hyperhidrosis is not well understood,
evidence suggests it is due to abnormalities in the autonomic nervous system rather than increase
in gland size or number.4 Some studies postulate sympathetic nervous system overactivity, while
others point to a more complex mechanism involving parasympathetic pathways as well.4 In
addition, there is a suggested genetic component, as 25% of patients suffering from the condition
have a positive family history of hyperhidrosis.3
The suggested diagnostic criteria for primary hyperhidrosis are as follows: visible
excessive sweating without an identifiable cause for at least 6 months plus at least two of the
following: bilateral and symmetric distribution pattern, impairment of daily activities, sweating
episode occurring at least one time weekly, age of onset under 25 years old, positive family
history, and a discontinuation of sweating during sleep.5
Hyperhidrosis affects approximately 4.8% of the United States population, correlating to
about 15.3 million people.6 An epidemiological study found females to be affected at slightly
higher rates than males (62.8% female) when analyzing records from the U.S. and Canada. This
study additionally noted axillary hyperhidrosis to be the most common location for patient
complaints (73% of complaints).1 Prevalence is highest among individuals aged 18-39 and lowest
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among those at the extremes of age. Of the estimated 15.3 million individuals suffering from
hyperhidrosis, it is predicted that only about half will seek medical attention; the condition is
both underreported and underdiagnosed.6
The impacts of hyperhidrosis extend far beyond the discomfort of excessive sweating.
This condition can have a negative impact on many areas of life. It may lead to low self-esteem,
depression, anxiety, suicidal ideation, social withdrawal, embarrassment, and can significantly
interfere with daily activities, relationships, and work.6-8 One study found that “over half of the
participants (54%) claimed they would pay anything for a treatment to stop their excessive
sweating”.6 Furthermore, it can significantly increase patient risk for cutaneous infections
including higher risk of bacterial, fungal and viral infection, as well as increased risk of
dermatophytosis and verruca.9 The wide range of negative impacts demonstrates how
significantly individuals can be affected and how important it is to find an effective and practical
treatment for the condition.
Typical treatment options include topical antiperspirants such as aluminum chloride
hexahydrate.10 While these agents tend to be first line, successful treatment may require
reapplication every 6-8 hours and concentrations up to 30% to be effective, often leading to skin
irritation.11 Other options include anticholinergic medications (glycopyrrolate 1-2 mg PO tid or
oxybutinin 5 mg PO tid).3,10 A systematic review demonstrated an average improvement in
symptoms of 76.2% with oxybutynin therapy, however 73.4% of patients taking oxybutynin
experienced dry mouth, leading a percentage of participants to cease therapy. Other adverse
effects noted were headache, urinary retention, gastrointestinal upset, heart palpitations and dry
eyes.12 More invasive approaches include ganglionectomy or sympathectomy.3
Onabotulinumtoxin type A (BTX-A) is yet another treatment option available; it is a
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neuromuscular blocking agent that blocks acetylcholine release from the presynaptic membranes
creating a denervation state.13 Ordinarily, as part of the sympathetic nervous system response,
acetylcholine binding to muscarinic receptors on sweat glands will activate sweating.14
Therefore, with blockage of acetylcholine release, the sweating response is inhibited with
onabotulinumtoxin. Local injection of BTX-A is being evaluated in this review due to its
practicality with onset of action being 1-3 days, fast recovery time, the minimally invasive nature
of the procedure, and long-lasting effects from the injection (approximately 4-6 months).15

OBJECTIVE
The objective of this selective EBM review is to determine whether or not “Does
onabotulinumtoxin type A reduce interference of daily activities for adults with hyperhidrosis?”

METHODS
Three randomized control trials (RCTs) published in peer-reviewed journals after the date
of 2009 were used in this selective evidence-based medicine (EBM) review. The patient
population addressed were those suffering from primary hyperhidrosis that were over 18 years of
age. The intervention applied in these studies was a form of onabotulinumtoxin type A (BTX-A).
Groups receiving BTX-A were compared to groups receiving other treatment modalities
(incobultinumtoxin A injections, suction-curretage procedure) and a control group (liposomal
cream without botulinum toxin).16-18 Each study chosen utilized the hyperhidrosis disease
severity scale (HDSS) as part of the outcome measures. The HDSS is a subjective scale graded
1-4 based on how severely sweating interrupts daily activities.19
The databases Pubmed, CINAHL plus, International Pharmaceutical Abstracts, and
Central Register of Controlled Trials were searched using the key words: “hyperhidrosis”,
“botulinum toxin” and “Botox”. The selected articles were published in peer-reviewed journals

Richardson, Onabotulinumtoxin for hyperhidrosis
4
and written in the English language. Articles were selected based on their applicability to the
clinical question being asked, which articles offered the greatest validity, as well as being
patient-oriented outcomes that matter (POEMs). Inclusion criteria for this systematic review
included RCTs published after 2009. Exclusion criteria was studies using patients under 18 years
of age, studies focused on secondary hyperhidrosis, as well as if the article was a systematic
review or meta-analysis. Statistics consistently used across all articles was a change from
baseline of HDSS scores before and after intervention. Table 1 outlines the demographics and
characteristics of the chosen studies.

OUTCOMES MEASURED
All three RCTS in this review addressed outcomes that are considered POEMs (patientoriented evidence that matters).16-18 The POEM being addressed in this review is a reduction in
the interference of daily activities from sweating due to primary hyperhidrosis. This reduction in
daily activity interference was measured using the hyperhidrosis disease severity scale (HDSS), a
subjective scale graded 1-4. A score of one is least severe correlating to no daily activity
interference due to sweating, while a score of four is considered the most severe, correlating to
sweating “always” interfering with daily activities.19 In the RCTs, the HDSS was administered
before intervention with onabotulinumtoxin type A (BTX-A) and then re-administered after the
intervention with onabotulinumtoxin type A. In two studies, mean HDSS scores were calculated
both prior to intervention with BTX-A and again following intervention. These mean scores were
then compared to one another to determine if the reduction was considered statistically
significant, defined as a p-value <.05.16,17 In Lueangarun et al., baseline and post-intervention
HDSS scores were compared. However, in this study, the statistical significance was based upon
the comparison in HDSS reduction of the experimental group (BTX-A) to the control group.18
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Table 1. Demographics and Characteristics of Included Studies.16-18
Study

Type

#
Pts

Age
(yrs)

Inclusion Criteria

Exclusion Criteria

W/D

Interventions

Ibraham
O,
Kakar
R,
Bolotin
D, et al.
2013.16

RCT

20

18-65
y/o

Patients diagnosed
with bilateral
axillary
hyperhidrosis, in
“good health” and a
BMI between 18.5
and 29.9.

Pregnant, lactating pts.
Past suction/curettage
treatment. Axillary BTA injections 12 months
prior, on blood
thinners/hx of bleeding
d/o. Sore or infection
near procedure site.
Known sensitivity to
iodine, starch powder,
albumin, BTX product.

0

Onabotulinum
toxin type A
injections
versus
suctioncurettage
treatment

Campan
ati A,
Giuliod
ori K, et
al.
2014.17

RCT

25

19-50
y/o

Patients with
moderate to severe
primary palmar
hyperhidrosis that
were resistant to
antiperspirants that
contained aluminum
chloride or
iontophoresis.

Pregnant or nursing
women. If ever received
incobotulinumtoxin or
oncobotulinumtoxin
type A ever in the past.
Pts treated with
aluminum chloride or
iontophoresis less than
3 months before the
study start.

0

Onabotulinum
toxin type A
injections
versus
Incobotulinum
toxin type A
injections.

Lueanga
run S,
Sermsli
p C,
Tempar
k T.
2018.18

RCT

20

18-50
y/o

Pts w/ symmetric
bilateral primary
axillary
hyperhidrosis. Initial
HDSS scores of 2-4,
and who have not
previously received
specific types of
treatment for the
condition w/i 6
months of the trial.

Pregnancy, lactation,
previous botulinum
toxin injections/
microwave thermolysis/
High intensity US/hair
removal laser within 6
months before
screening. Pts with
more than 25%
asymmetry between
axilla. Use of
anticholinergics. Hx of
specific medical
conditions.

Not
stated

Topical
botulinum
toxin type A
liposomal
cream versus
vehicle cream
without.
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RESULTS
Ibrahim et al., conducted a randomized control trial composed of 20 subjects to compare
the effectiveness of onabotulinumtoxin-A (BTX-A) injections to a suction-curettage procedure.16
Patients between the ages of 18 to 65 were included if they had a prior diagnosis of bilateral
axillary hyperhidrosis, were in “good health” and had a BMI between 18.5 and 29.99. Exclusion
criteria omitted patients who were pregnant or lactating and those who had undergone a suctioncurettage procedure in the past or had BTX-A injections within the previous 12 months. It
additionally excluded anticoagulated patients, those with a sore or infection near the procedure
site and patients with sensitivities to products being utilized in the study.16 Each patient received
BTX-A injections in one axilla and had the suction-curettage procedure performed on the
opposing axilla. Which procedure was performed on the right versus left axilla was allocated via
random sequence generation. The axilla receiving BTX-A injections had a total of 50 U of toxin
given via 0.5 inch 30-guage needle; this was achieved with dermal deposits of 0.1-0.2 mL spaced
evenly at 1.5-2cm apart. Due to obvious differences in procedures, blinding was unable to be
achieved by patients and those administering the interventions. There were no losses to followup during the study. Mean HDSS scores were calculated both before any intervention, and three
months following intervention. Data collected was continuous data (see Table 2). The results of
the study demonstrate that the BTX-A injections were effective in achieving a statistically
significant reduction in interference of daily activities (P<.001) following the intervention.16
While my clinical question is not focusing on other treatments, it is of note that when comparing
BTX-A versus suction curettage the mean reduction in HDSS scores at three months, the
injections caused a larger decrease (0.75 point difference among groups), however it was not
addressed in the article if this difference was statistically significant. Importantly, no subjects
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reported discomfort or adverse reactions to the BTX-A injections, while soreness,
hyperpigmentation (15% subjects), dysesthesia (5% subjects) were noted following the suctioncurettage procedure.16 These results can help guide future clinical decision making when
discussing treatment options with patients in terms of efficacy and tolerability.
Table 2. Comparison of Mean Reduction in HDSS Scores of BTX-A Injections versus Suctioncurettage Procedure.16
Baseline mean
3 months post
Mean change from
HDSS scores
intervention mean
baseline (points) and p(points)
HDSS scores (points) value
Axilla receiving
3
1.45
1.55, P <.001
BTX-A injections
Axilla receiving
3.05
2.25
0.8, P <.001
suction-curettage
procedure
Table 3. Adverse Side Effects Associated with BTX-A Injections versus Suction-curettage
Procedure.16
Percentage experiencing
Percentage experiencing
hyperpigmentation after
noteworthy dysesthesia after
procedure
procedure
BTX-A injections
0%
0%
Suction-curettage
15%
5%
procedure
Campanati et al., conducted a double-blind randomized control trial with 25 subjects
comparing the efficacy of onabotulinumtoxin-A (BTX-A) injections to incobotulinumtoxin
injections for patients with moderate to severe primary palmar hyperhidrosis.17 The study
included patients aged 19-50 (15 female and 10 male) that were resistant to past aluminum
chloride or iontophoresis interventions. Subjects were excluded from the study if they were
pregnant, nursing, had received treatment with aluminum chloride or iontophoresis within 3
months of trial, or any prior history of BTX-A or incobotulinumtoxin injections. In this trial, all
patients received BTX-A injections and incobotulinumtoxin injections on contralateral hands.
There was no statistically significant difference of sweating extension between hands at the start
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of the trial. Reference grids were drawn on subjects’ hands with square areas of 2.25 cm2.
Product was diluted in a 5mL sterile 0.9% saline solution and 0.1mL was administered by a
physician in the center of each square via a 30-guage needle. Which product was injected in the
right versus left hand was done in a random order with both patients and physicians blinded to
the product being administered.17 At the conclusion of the trial, no patients were lost to followup. Data presented was continuous. HDSS scores were obtained at baseline (prior to any
intervention) and 4 weeks following injections. Mean HDSS scores at baseline were 2.45 for
both groups; the mean HDSS scores for each group following intervention were not explicitly
stated in the article, however it was reported that all patients experienced a 2-point decrease in
their score from baseline regardless of intervention given (see Table 4). This was considered a
therapeutic success for both interventions and statistically significant change from baseline
following either treatment (P<.001).17
Table 4. Comparison of HDSS Sores before and after Interventions with BTX-A and
Incobotulinum Toxin Injections. (Numbers in this chart are estimated based on Figure 2 in the
published study).17
Mean HDSS score at baseline
Mean HDSS scores 4 weeks after
(prior to intervention)
intervention
BTX-A injections
2.45
Not explicitly stated in article.
Incobotulinumtoxin-A
2.45
Not explicitly stated in article.
injections
Lueangarun S et al., conducted a double-blind RCT comparing a topical
onabotulinumtoxin type A (BTX-A) liposomal cream to a control group liposomal cream
containing no active ingredient.18 This study utilized 20 subjects with symmetric bilateral
primary axillary hyperhidrosis aged 18-50 years old. To qualify, patients needed to have initial
HDSS scores between 2-4. The trial excluded pregnant and lactating patients as well as those
who had previous BTX-A injections, microwave thermolysis, high intensity ultrasound, or hair
laser removal within 6 months of the screening process. Additionally, those with more than 25%
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asymmetry between axilla, taking certain medications (CCB, anti-cholinergics, aminoglycosides)
or those with certain medical conditions (CHF, DM, hyperthyroidism, myasthenia gravis) were
excluded.18 Subjects were randomly given two bottles of cream (one for each axilla, one cream
with BTX-A and one without). Instructions were to use two pumps of cream from each bottle
and consistently apply it to the same axilla each night for 7 days. The results were presented as
continuous data. At baseline, the starting HDSS score was 3.1. After four weeks of cream use,
the HDSS score was 1.75 for axilla treated with BTX-A cream versus a score of 2.65 for axilla
treated with the control cream (see Table 5). This was a statistically significant reduction in
scores when comparing the BTX-A cream to the control cream (P<.001) translating to a
reduction in interference of daily activities with use of cream containing BTX-A.18 It is
presumed that these scores represent a mean score of all 20 subjects (a mean change from
baseline), however this was not explicitly stated. It was also not clear that all subjects completed
the trial. In this study, no adverse effects were observed with either liposomal cream; this
indicated a good safety profile as no rash, pruritis, burning, changes to skin color or skin
eruptions occurred during the trial.18
Table 5. Comparison of HDSS Scores before and after Onabotulinumtoxin type A (infused)
Liposomal Cream versus Control Cream.18
HDSS at baseline
HDSS after four weeks of cream usage
Liposomal cream
3.1
1.75
with BTX-A
Control liposomal
3.1
2.65
cream with no active
ingredient
P <.001
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DISCUSSION
Primary hyperhidrosis is a chronic idiopathic condition characterized by excessive
perspiration that can have debilitating psychological, health and behavioral effects on those
suffering from it.1,6 This selective EBM review sought to answer whether or not
onabotulinumtoxin type A is effective in reducing the interference of daily activities for those
suffering from primary hyperhidrosis. All three RCTs analyzed in this review demonstrated that
BTX-A was effective in reducing HDSS scores (all statistically significant), thus correlating to a
reduction in daily activity interference.
It is important to mention the multiple limitations with the studies reviewed. In all three
studies the sample size was quite small (20-25 people), therefore it cannot be assumed the results
of these studies are applicable to the general population.16-18 In addition, there was no
demographic information given about ethnicity in the articles chosen, thus it is unclear how
ethnicity would affect the generalizability of the results. All three RCTs excluded pregnant or
nursing women, so results found are not applicable to this patient population.16-18 Additionally,
Ibrahim et al., excluded those with a BMI outside of the range (18.5-29.99), and all procedures
were performed at the same location by the same physician, therefore it must be kept in mind
that these results may not apply to those with BMIs outside of the given range, or for those
getting procedures performed at other facilities by other physicians.16 In Campanati et al.
randomization allocation was not concealed from those enrolling subjects.17 In Lueangarun et
al., 80% of subjects were female, so it is difficult to discern if the results of this study are
applicable to men. Those with certain comorbidities or on specific medications were excluded,
therefore efficacy and safety profiles cannot be applied to those with the exclusionary
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medications and conditions. In addition, the trial was only double-blind not triple blind and
losses to follow-up were not addressed.18
Onabotulinumtoxin type A is a neuromuscular blocking agent. It works at the
neuromuscular junction by blocking acetylcholine release from presynaptic membranes creating
a denervation state.13 There are many uses for BTX-A including glabellar, forehead and canthal
lines, cervical dystonia, chronic migraine, overactive bladder, and urinary incontinence to name a
few.13 Contraindications include known hypersensitivity, or infection at the injection site. Data is
limited with pregnant or nursing mothers and therefore it is not recommended for those pregnant
or nursing. While no serious reactions occurred in the reviewed articles,16-18 severe reactions may
occur. These include anaphylaxis, arrythmias, myocardial infarction, and systemic toxicity due to
distant toxin spread. Distant toxin spread may lead to dysphagia and breathing difficulties that
are life-threatening.13 Drug interactions are noted with aminoglycosides, anticholinergic agents,
muscle relaxants, and using multiple agents containing onabotulinumtoxin type A at the same
time. Pricing for 100 units in the U.S. is $721.21.13 Reimbursement and out-of-pocket expenses
can vary based on insurance coverage,20 therefore cost may be a limiting factor for some.

CONCLUSIONS
All three RCTs demonstrated that onabotulinumtoxin type A was effective in reducing
the interference of daily activities for adults with primary hyperhidrosis.16-18 Thus, it is
reasonable to conclude that BTX-A is an effective and reasonable choice of intervention to
enhance the daily lives of adults suffering from primary hyperhidrosis.
Future research should include larger sample sizes and have BTX-A injections performed
at different sites by different providers to increase the generalizability of the research. In
addition, the cream application of BTX-A is an interesting area for further studies, as it broadens
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treatment options for those who are uncomfortable with needles and the pain associated with
injections. If more research is done on efficacy, safety, and the most appropriate form of topical
BTX-A administration, it could be a potential treatment option for patient populations that prefer
a once daily application to intermittent injections.
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